Sarah Ontiveros
Primary Care · Glendale, AZNPI 1043695018
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $809 of the $908 with a category attached, or 89.1%. 13 manufacturers reported payments, led by Progenics Pharmaceuticals, Inc. at 25.6% of the total. Reporting peaked in 2024 at $330 and has fallen 53.7% since, to $153 in 2025.
Across 24 payments — averaging $37.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Progenics Pharmaceuticals, Inc.$233
- Daiichi Sankyo Inc.$190
- Cvrx, Inc.$145
- Novartis$67
- Pfizer$62
- Ferring Pharmaceuticals Inc.$58
- plus $154 from 7 others
What the payments were for
- Food & beverage$80989%
- Education$9911%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Progenics Pharmaceuticals, Inc. | 2 | $233 |
| Daiichi Sankyo Inc. | 5 | $190 |
| Cvrx, Inc. | 1 | $145 |
| Novartis | 3 | $67 |
| Pfizer | 3 | $62 |
| Ferring Pharmaceuticals Inc. | 2 | $58 |
| Merck | 2 | $52 |
| Seagen Inc. | 1 | $23 |
| Stemline Therapeutics Inc. | 1 | $21 |
| Eisai Inc. | 1 | $17 |
| Bayer | 1 | $15 |
| Amgen | 1 | $14 |
| Johnson & Johnson | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PYLARIFY$233
- Barostim Neo System$145
How this compares
$908 in reported general payments places this provider in the 60th percentile of 151 primary care providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tamsulosin Hcl | 165 | $3,029 |
| Solifenacin Succinate | 11 | $242 |
| Ciprofloxacin Hcl | 84 | $145 |
| Levofloxacin | 40 | $82 |
Paid to pharmacies, not to this prescriber.
Other primary care in Glendale
- Hetal TrivediGlendale$2K
- Catherine SmyserGlendale$1K
- Roberto RamirezGlendale$1K
- Trey PowrzanasPhoenix$16K
- Christine Rocks-LopezPhoenix$14K
- Elena KlimovaPhoenix$8K
- Albert VillafaniaPhoenix$8K
- Daniela HaimovPhoenix$8K
- Lea NickolasAvondale$7K
- Neena VargheseSacaton$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.